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Abstract 
Bromodomain and extra-terminal domain (BET) BRD4 binds to acetylated histones at 
enhancers and promoters through conserved bromodomains (BDs) to function as a 
master regulator of transcriptional elongation. Here, we reveal through global profiling 
analysis, an extensive recruitment of BRD4 at active enhancers that are co-occupied by 
mutant p53 and support the synthesis of enhancer-directed (eRNA) transcripts in 
response to chronic immune signaling. We identify that BRD4 is a highly robust binding 
module for RNAs and that there exists marked selectivity of BRD4 associations with 
eRNAs that are produced from enhancers bound by BRD4. Through biochemical and 
biophysical characterizations, we show that BRD4 BDs function cooperatively as 
docking sites for eRNAs and that the BDs of BRD2, BRD3, BRDT, BRG1, and BRD7 
also interact directly with eRNAs. BRD4-eRNA interactions increase BRD4 binding to 
acetylated histones and promote enhanced BRD4 recruitment at specific enhancers that 
in turn augments BRD4 transcriptional activities. This work provides a previously 
unrecognized convergence between eRNAs and histone posttranslational modifications 
in regulating BRD4 binding and highlights a mechanism by which eRNAs play a direct 
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role in gene regulation by modulating enhancer interactions and transcriptional 
functions of BRD4.  
Main 
Enhancers shape gene expression programs that drive cellular processes by acting to coalesce 
information from environmental stimuli and the coordinated activities of multiple 
transcription factors and cofactors1-5. Our ability to predict and annotate enhancers and their 
activity states across multiple cell and tissue types stems from the identification of distinct 
epigenomic signatures that include an accumulation of the histone marks, histone H3 lysine 4 
monomethylation (H3K4me1) that together with histone H3 lysine 27 acetylation (H3K27ac) 
demarcates active enhancers3,6,7-9. Histone lysine acetylation plays a critical role in the 
context of chromatin, most generally by contributing to chromatin accessibility and 
transcriptional activation10. A diverse number of transcriptional coregulators and chromatin 
modifying enzymes bind to acetylated histones through bromodomain (BD) modules, 
particularly at active enhancers11. The affinity and selectivity of BD interactions with 
acetylated lysine residues are typically weak in nature, but can be increased by BD 
interactions with multiple and neighboring acetylation sites within the histone tail12-14, 
suggesting that additional mechanisms regulating BD binding at enhancers are likely to have 
important implications for chromatin regulation and transcription.   
The bromodomain and extraterminal motif (BET) proteins are among the well-known 
proteins that bind to histone acetylation through their tandem amino-terminal BDs (BD1 and 
BD2)11,15. BRD4, a well-studied member of the BET family binds to acetylated histones and 
non-histone proteins at enhancers and promoters11,16-18 to regulate gene expression programs 
that play particularly pivotal roles in inflammation and cancer development19-21. BRD4 has 
been shown to associate with multiple transcriptional regulators, that include TWIST, p53, 
C/EBPα, C/EBPβ, ERG, and NFκB, which has provided increasing support of its role in 
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enhancer and gene regulation22-28. Most recently, BRD4 enhancer binding was shown to 
modulate gene expression to control cellular identity during adipogenesis and myogenesis29. 
Highly selective inhibitors of the BET family including JQ1 have demonstrated that BRD4 
binding at enhancers supports eRNA production30 and super-enhancer formation31-33. In 
addition, BRD4 promotes RNAPII elongation at enhancers and within protein-coding genes 
through its recruitment of the active form of Positive Elongation Factor-b (P-TEFb)34,35 and 
by its ability to exhibit histone chaperone activity to overcome nucleosomal barriers for 
elongating RNAPII36. While there are clear links between BRD4 and context-dependent gene 
regulation, the molecular mechanisms underlying the enhancer and gene-specific targeting 
and functions of BRD4 remain elusive.  
The widespread synthesis of eRNAs that is regulated by transcriptional cofactors such 
as BRD4 serves as a measure of enhancer activity and has been implicated in the regulation 
of gene expression in multiple cell types and in response to different stimuli37,38. Various 
roles of eRNAs have stemmed from recent studies linking eRNAs to enhancer-promoter 
interaction interfaces39,40, chromatin remodeling41, the release of paused RNAPII42, and the 
recruitment of general cofactors that include cohesin39,40, Mediator41,43, and the histone 
acetyltransferase CBP44. While eRNAs are well positioned to dynamically remodel cellular 
transcriptomes and add a new layer of complexity to gene regulation, the molecular basis by 
which eRNAs function in enhancer and gene regulation, and their connection with other 
epigenetic features at active enhancers remain poorly understood.  
 In this study, we show that RNAs directly interact with the BDs of BRD4, and that 
similar RNA interactions exist for the BDs of all BET family members and non-BET 
proteins, BRG1 and BRD7. Notably, we find that eRNAs exhibit cooperativity with 
acetylated histone lysines in vitro and at active enhancers to augment BRD4 binding and 
transcriptional activity. Collectively, our results provide evidence for a feedforward 
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epigenetic mechanism in which eRNAs through direct interactions with BRD4 support an 
active enhancer landscape that modulates proinflammatory gene expression.  
Results 
BRD4 binds and functions at p53 R273H bound enhancers in response to chronic TNF-
α signaling 
Since BRD4 has been shown to occupy and regulate enhancer function33,45-47, we 
sought to investigate whether BRD4 regulates recently identified signal-dependent enhancers 
that are activated by mutant p53 in response to chronic immune signaling48. Using genome-
wide chromatin immunoprecipitation followed by sequencing (ChIP-seq) in human SW480 
colon cancer cells, expressing the hotspot mutant p53 R273H (hereafter mutp53) and treated 
with tumor necrosis factor alpha (TNF-α) for 16 hr, we identified stringent BRD4 binding 
peaks (n=21,528, p-value < 10-5). Comparative analyses of the BRD4 binding peaks with our 
previously published mutp53, H3K4me1, and H3K27ac ChIP-seq data in response to chronic 
TNF-α signaling48 showed a striking colocalization of BRD4 binding peaks with the peak 
sites for mutp53 and the histone marks H3K4me1 and H3K27ac, which demarcate active 
enhancers (Fig. 1a). Specifically, we identified that approximately a third (28%, n=5,949, p-
value < 10-5) of the total BRD4 binding sites occur at intergenic sites overlapping with active 
enhancers (Supplementary Fig. 1a). Remarkably, over 80% (n= 4,884, p-value < 10-5) of the 
BRD4 binding sites that overlap with active enhancers are also occupied by mutp53 
(Supplementary Fig. 1a). Furthermore, de novo motif analysis identified that NFκB/p65 and 
EWS:ERG fusion (ETS) consensus motifs are among the most highly enriched motifs to 
overlap with the BRD4 and mutp53 peaks (Supplementary Fig. 1b). This analysis is 
consistent with our previous findings that NFκB plays a significant role in the recruitment of 
mutp53 at active enhancers in response to chronic immune signaling48. To investigate 
whether mutp53 and BRD4 simultaneously bind active enhancers in response to TNF-α-
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signaling, sequential ChIP was performed and the precipitated DNA was analyzed by 
quantitative PCR (qPCR) using primer sets designed against the enhancer (amplicon A) and 
downstream control (amplicon B) regions of the MMP9 and CCL2 enhancers, which are 
among the signal-dependent enhancers that we recently found to be bound and activated by 
mutp53 and NFκB in response to chronic TNF-α signaling48. In response to chronic TNF-α 
signaling, selective and simultaneous binding of mutp53 and BRD4 was observed at the 
MMP9 and CCL2 enhancers, but not the control regions (Supplementary Fig. 1c). We also 
identified that BRD4 and mutp53 form comparable physiological associations in SW480 cells 
before and following TNF-α treatment as revealed by co-immunoprecipitation (Co-IP) 
analyses with an antibody specific to BRD4 (Supplementary Fig. 1d). Using purified 
proteins, we also revealed that BRD4 forms direct interactions with mutp53 and wild-type 
(WT) p53 (Supplementary Fig. 1e), which is similar to previous reports revealing an 
interaction between BRD4 and WT p5324. We next assessed whether mutp53 contributes to 
BRD4 binding at enhancers by performing ChIP-qPCR analyses in SW480 cells expressing 
doxycycline-inducible short hairpin RNAs (shRNAs) against mutp53 following TNF-α 
treatment for 16 hr. Relative to a non-targeting shRNA against LacZ (Ctrl), p53 shRNA 
markedly reduced mutp53 protein levels after TNF-α treatment without affecting BRD4 
protein levels (Supplementary Fig. 1f). As shown in Fig. 1b, mutp53 knockdown resulted in a 
comparable loss (approximately 66% and 72%) of mutp53 binding at the MMP9 and CCL2 
enhancer regions, respectively. Notably, this decrease in mutp53 binding resulted in a 
significant reduction in BRD4 binding at the MMP9 (52%) and CCL2 (65%) enhancers (Fig. 
1b). Together, these results establish functional mutp53-BRD4 interactions that are consistent 
with the colocalization of mutp53 and BRD4 across the genome and further underscore the 
requirement for mutp53 in regulating BRD4 binding at active enhancers in response to 
chronic TNF-α signaling. 
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To determine whether BRD4 contributes to the regulation of BRD4 and mutp53 co-
bound enhancers, we next examined the global levels of nascent transcription (+/- TNF-α) 
centered upon the enhancer-specific BRD4 and mutp53 ChIP-seq peaks using our global run-
on sequencing (GRO-seq) data48. As revealed in Fig. 1c, markedly induced eRNA levels 
following 16 hr TNF-α treatment were identified at H3K27ac-enriched intergenic sites that 
are co-occupied by BRD4 and mutp53. Notably, the TNF-induced eRNA levels observed at 
the mutp53 and BRD4 co-bound enhancers were significantly higher relative to eRNA levels 
at H3K27ac-enriched intergenic sites that were not co-bound by BRD4 and mutp53 and in 
response to chronic TNF signaling. To examine a direct role for BRD4 in the regulation of 
TNF-α-induced enhancer transcription, we established SW480 cells stably expressing 
nontargeting (Ctrl) or two different shRNA oligonucleotides specific to BRD4 (BRD4-1 and 
BRD4-2). As shown in Fig. 1d, relative to the control knockdown, both shRNAs against 
BRD4 significantly and comparably decreased BRD4 mRNA and protein levels. ChIP-qPCR 
analyses in control knockdown cells (+/- TNF-α) revealed that BRD4 binding at the active 
enhancers adjacent to the MMP9 and CCL2 gene loci is significantly increased (53% and 
70%, respectively) in response to chronic TNF-α signaling (Fig. 1e). As expected, BRD4 
knockdown resulted in a significant loss in TNF-α-inducible BRD4 binding that occurs at the 
MMP9 and CCL2 enhancers (55% and 63%, respectively) (Fig. 1e). Notably, this decrease in 
TNF-α-induced BRD4 binding resulted in a significant loss in the TNF-α-inducible eRNA 
levels of MMP9 and CCL2 (four-fold and six-fold, respectively) and a comparable (two-fold) 
decrease in the TNF-α-induced mRNA levels of both MMP9 and CCL2 (Fig. 1f; 
Supplementary Fig. 1g). In comparison, under uninduced conditions, little to no effect on 
BRD4 binding and eRNA/mRNA expression levels was identified at the MMP9 and CCL2 
enhancers following BRD4 shRNA-mediated knockdown (Figs. 1e,f; Supplementary Fig. 
1g). The significant reduction in the TNF-α-induced MMP9 and CCL2 eRNA and mRNA 
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expression levels following BRD4 knockdown was found to be independent of a decrease in 
mutp53 binding at the MMP9 and CCL2 enhancers (Supplementary Fig. 1h). This data, taken 
together with our mutp53 shRNA-mediated knockdown data, which revealed a significant 
loss in TNF-α-induced BRD4 binding at the MMP9 and CCL2 enhancers (Fig. 1b), 
demonstrates that while mutp53 is required for BRD4 binding, BRD4 is not required to 
support mutp53 at this subset of enhancers. Consistent with our results following shRNA-
mediated BRD4 knockdown (Fig. 1f; Supplementary Fig. 1g), treatment of SW480 cells with 
the BET inhibitor, JQ145, which did not affect BRD4 protein levels (Supplementary Fig. 1i), 
resulted in a significant decrease in the TNF-α-inducible MMP9 and CCL2 eRNA and 
mRNA levels. This identified role for BRD4 in regulating the TNF-induced expression of 
eRNAs and tumor promoting genes is consistent with our previous observations revealing 
that mutp53 is also required to support TNF-α-inducible eRNA/mRNA expression levels in 
SW480 colon cancer cells48. Collectively, these data strongly suggest that BRD4 acts 
coordinately with mutp53 at active enhancers to support potent levels of eRNA synthesis and 
nearby gene expression in response to chronic TNF-α signaling. 
BRD4 associates with RNAs synthesized from genomic regions occupied by BRD4 
Given the significant overlap between BRD4 enrichment and potent eRNA synthesis 
in response to chronic TNF-α signaling and the previously described association of BRD4 
with RNAPII elongation complexes36, we examined whether BRD4 associates with RNAs 
under physiological conditions by performing UV-crosslinked RNA immunoprecipitation 
(UV-RIP) in SW480 cells (+/- TNF-α). BRD4 mRNA and protein levels were found to be 
unaffected by chronic TNF-α treatment in this cell line (Supplementary Fig. 2a). In TNF-α-
treated SW480 cells, we found that a BRD4 antibody specifically co-immunoprecipitated 
eRNAs produced from the MMP9, CCL2, CSF2, and TNFAIP3 but not the TFAP2A and 
MPP7 enhancers (Fig. 2a; Supplementary Fig. 2b) despite that the TFAP2A and MPP7 
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eRNAs were expressed at comparable or even higher levels relative to the MMP9, CCL2, 
CSF2, and TNFAIP3 eRNAs as revealed by our GRO-seq data (Fig. 2c; Supplementary Fig. 
2c). We also found that BRD4 associates with MMP9 and CCL2 mRNAs but not the 
TFAP2A and MPP7 mRNAs in response to chronic TNF-α signaling (Fig. 2b). In 
comparison, under uninduced conditions, BRD4 was not found to associate with any of the 
examined MMP9, CCL2, TFAP2A, MPP7, CSF2, and TNFAIP3 RNAs (Figs. 2a,b; 
Supplementary Fig. 2b). The specific association of BRD4 with RNAs in response to chronic 
TNF-α signaling is consistent with the significantly higher expression levels of these RNAs 
in the TNF-α-induced versus uninduced cells as demonstrated by our GRO-seq data (Fig. 2c; 
Supplementary Fig. 2c). Notably, BRD4-RNA associations are also consistent with BRD4 
binding levels, which were found to be significantly higher at the MMP9 and CCL2 relative 
to the TFAP2A and MPP7 enhancers and transcription start sites (TSSs) in response to 
chronic TNF-α signaling as demonstrated by our BRD4 ChIP-seq data (Fig. 2d). Also 
consistent, is the identification that the TNF-α-induced associations of BRD4 with the CSF2 
and TNFAIP3 eRNAs (Supplementary Fig. 2b) parallels with the high levels of BRD4 
binding at the CSF2 and TNFAIP3 enhancers (Supplementary Fig. 2c).  
Having identified a physiological association between BRD4 and RNAs that are 
produced from genomic regions occupied by BRD4 in response to chronic TNF-α signaling, 
we next examined whether recombinant BRD4 full-length (FL) directly interacts with in vitro 
transcribed eRNAs, as well as several other RNA molecules including long noncoding RNAs 
(lncRNAs) and exonic RNAs. Consistent with our UV-RIP analyses in SW480 cells, we 
identified that BRD4 interacts directly with the MMP9 and CCL2 eRNAs (Supplementary 
Fig. 2d). In addition, we also found that BRD4 directly interacts with the MEG3 lncRNA and 
the p21 exonic RNA (Supplementary Fig. 2d). Together with our UV-RIP analyses, these 
findings suggest that BRD4 displays broad rather than sequence-specific RNA interactions 
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and that BRD4-eRNA associations occur in an enhancer- and locus-specific manner such that 
BRD4 associates with specific RNAs synthesized from genomic regions that are significantly 
enriched for BRD4 binding in response to chronic TNF-α signaling. 
BRD4 directly interacts with eRNAs through its tandem bromodomains 
Having established physiological and direct interactions between BRD4 and RNAs, 
we further investigated the direct binding of BRD4 to eRNAs. RNA electrophoretic mobility 
shift assays (EMSAs) were performed using purified BRD4 FL and a 32P-labeled MMP9 
eRNA probe. As revealed in Fig. 3a, we observed the formation of a single prominent BRD4-
MMP9 eRNA complex. Quantification of the RNA EMSA with increasing doses of BRD4 
FL revealed that ~80% of the MMP9 eRNA was bound by BRD4 FL at the highest titration 
of BRD4 FL protein (Supplementary Fig. 2e). To further test the specificity of BRD4-MMP9 
eRNA interactions, competition EMSAs were performed in the presence of increasing 
amounts of unlabeled CCL2 eRNA or a single strand MMP9 DNA probe. BRD4 binding to 
the labeled MMP9 eRNA probe was specifically competed by excess amounts of cold CCL2 
eRNA (Fig. 3b). In comparison, identical amounts of the MMP9 ssDNA were significantly 
less efficient in competing BRD4-MMP9 eRNA interactions (Fig. 3b), which demonstrates 
that BRD4 binds preferentially to RNA sequences in vitro.  
To identify the specific domains of BRD4 that contribute to interactions with eRNAs, 
we next performed RNA pulldown assays using BRD4 deletion mutants (Fig. 3c) and in vitro 
transcribed MMP9 and CCL2 eRNAs. Both recombinant BRD4 FL and the naturally existing 
short BRD4 isoform spanning from amino acids 1-72249 bind strongly and comparably to the 
MMP9 and CCL2 eRNAs (Fig. 3d). Next, we tested the contributions of the BRD4 
bromodomains (BDs) since these chromatin interacting domains localize within the eRNA 
interacting BRD4 (1-722) protein. As revealed by RNA pulldown assays, a truncated form of 
BRD4 that is devoid of both BDs (Fig. 3c, BRD4 ΔBD1/2) showed a nearly complete loss of 
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binding to the MMP9 and CCL2 eRNAs (Fig. 3d). Similarly, RNA EMSAs revealed that 
radiolabeled MMP9 eRNA did not display a robust mobility shift when titrated with BRD4 
ΔBD1/2 as compared to BRD4 FL (Fig. 3e). Specifically, we found that less than 5% relative 
to the nearly 80% of the labeled eRNA was bound by BRD4 ΔBD1/2 as compared to BRD4 
FL, respectively (Fig. 3e; Supplementary Fig. 2e). Together, the RNA pulldown assays and 
EMSA experiments reveal a requirement for the BDs in facilitating BRD4-eRNA 
interactions.  
We next tested whether the individual BRD4 BDs (Fig. 3c, BD1 or BD2) are 
sufficient to support BRD4-eRNA interactions by expressing and purifying the isolated BD1 
and BD2 domains. Notably, we found that neither BD1 nor BD2 are able to bind RNA as 
strongly as the BRD4 (1-722) protein as revealed by the significant decrease in their 
interactions with the MMP9 and CCL2 eRNAs (Fig. 3f). To further verify whether BD1 and 
BD2 are both required for eRNA interactions, we expressed and purified a longer BRD4 
protein (Fig. 3c; BRD4 BD1/2) consisting of both BDs and the linker sequence that joins 
BD1 and BD2, which revealed a level of eRNA binding that is comparable to BRD4 (1-722) 
(Fig. 3f). To expand upon the contributions of other BDs in facilitating eRNA interactions, 
we tested the BDs of additional BET family members, BRD2, BRD3, and BRDT as well as 
non-BET proteins, BRG1 and BRD7. As shown in Fig. 3g, the tandem BDs (BD1/2) of 
BRD2, BRD3, BRD4, BRDT, and the single BDs of BRG1 and BRD7 bind to MMP9 and 
CCL2 eRNAs with the eRNA interaction levels of BRG1 and BRDT relatively lower as 
compared to the other BD-containing proteins. Taken together, these findings demonstrate 
that BDs directly interact with eRNAs and that the tandem BRD4 BDs function cooperatively 
to facilitate BRD4-eRNA interactions.  
eRNAs enhance BRD4 binding to acetylated histone H3 and H4 peptides and 
reconstituted histone octamers  
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Having identified that eRNAs bind to the BRD4 BDs, which are known to support BRD4 
interactions with acetylated lysines50,51, we next investigated the significance of eRNA-BRD4 
interactions in the regulation of BRD4 binding to acetylated histones. First, in vitro binding 
assays were performed with K27ac-modified histone H3, K16ac-modified histone H4, or 
unmodified H3/H4 peptides. As expected, BRD4 FL (Figs. 4a,b lane 7 versus 3), but not 
BRD4 ΔBD1/2 (Figs. 4a,b lane 9 versus 5) bound more strongly to H3K27ac- and H4K16ac-
modified versus unmodified peptides. Notably, the binding of BRD4 FL to acetylated H3K27 
and H4K16 peptides was significantly increased in the presence of MMP9 eRNA (Figs. 4a,b 
lane 8 versus 7). In addition, eRNAs were not found to promote BRD4 binding in the absence 
of BRD4 interactions with acetylated peptides, as demonstrated by the inability of eRNAs to 
support BRD4 FL binding to unmodified histone H3 and H4 peptides (Figs. 4a,b lane 4 
versus 3) and the lack of an eRNA effect on BRD4 ΔBD1/2 binding to acetylated H3K27 and 
H4K16 peptides (Figs. 4a,b lane 10 versus 9).  
To further investigate the cooperativity between eRNAs and acetylated histones, we 
examined eRNA-dependent enhanced binding of BRD4 to histone octamers that were either 
unacetylated or acetylated by the histone acetyltransferase p300. As predicted, p300 
efficiently acetylated the histone octamers as demonstrated by the increased acetylation of 
H3K27 and H3K9 (Fig. 4c, lanes 3, 4 and 7, 8). In comparison, no acetylation was detected in 
the absence of p300 or acetyl-CoA (Fig. 4c, lanes 1, 2 and 5, 6). The acetylated histone 
octamers were coupled to magnetic beads using H3K27ac and H3K9ac antibodies and then 
incubated with BRD4 in the presence or absence of MMP9 eRNA. Notably and consistent 
with the histone peptide binding assay results, we found that MMP9 eRNA significantly 
increased BRD4 binding to acetylated histone octamers (Fig. 4c, lane 4 versus 3). Also 
consistent, the MMP9 eRNA had no effect on the binding of BRD4 ΔBD1/2 to the acetylated 
histone octamers (Fig. 4c, lanes 7 and 8 versus 5 and 6). The enhanced binding of BRD4 to 
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acetylated histone peptides and octamers in the presence of the MMP9 eRNA (Figs. 4a-c) 
was further confirmed in the presence of the CCL2 eRNA (Supplementary Figs. 3a,b). 
Moreover, by performing an eRNA titration experiment, we identified that several 
concentrations of the MMP9 eRNA revealed enhanced BRD4 binding to acetylated histone 
octamers (Supplementary Fig. 3c, lanes 3 and 4 versus 2). In addition, at high molar ratios of 
MMP9 eRNA to BRD4, the MMP9 eRNA was found to inhibit BRD4 binding to the 
acetylated histone octamers (Supplementary Fig. 3c, lanes 6 and 7 versus 2). Taken together, 
these findings establish that BRD4-RNA interactions enhance BRD4 binding to acetylated 
histone substrates in an RNA concentration-dependent manner.  
To gain insight into the steady state binding of BRD4 to acetylated histone H3 in the 
presence or absence of eRNAs, surface plasmon resonance (SPR) analyses were performed. 
Biotin-labeled H3K27ac-modified peptides were immobilized on a streptavidin-coated sensor 
chip surface and BRD4 BD1/2 was flowed over the chip surface at various concentrations 
(10, 15, 20 nM) in the presence or absence of MMP9 eRNA. Notably and as demonstrated by 
the resulting sensorgrams (Fig. 4d), the amount of BRD4 BD1/2 that bound to the H3K27ac-
modified peptides for all BRD4 protein concentrations was enhanced in the presence of 
MMP9 eRNA to yield an absolute level of binding approximately threefold higher than 
observed in the absence of eRNA. An appreciable dissociation was not detected as the 
targeted BRD4 BD1/2 remained bound to the H3K27ac-modified peptide during the time 
course of the experiments (Fig. 4d). Notably, the sensorgrams also demonstrated that all 
concentrations of BRD4 BD1/2 reached a significantly higher maximum binding capacity 
(Rmax) in the presence versus absence of eRNA (Fig. 4e). Specifically, the Rmax of BRD4 to 
the H3K27ac-modified peptide increased linearly in the presence of eRNA (Fig. 4e). 
Whereas BRD4 BD1/2 binding to the acetylated H3 peptide was saturated in the absence of 
eRNA (Fig. 4e). Notably, these biophysical data together with our biochemical findings 
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indicate that eRNA interactions with BRD4 BDs play a pivotal role in the enhanced binding 
of BRD4 to acetylated histones, in vitro.  
eRNAs regulate gene activation by modulating BRD4 enhancer occupancy and 
regulation of eRNA synthesis.  
To investigate the biological significance of BRD4-eRNA interactions, we first 
employed shRNA-mediated knockdown of eRNAs in SW480 cells (+/- TNF-α). qRT-PCR 
analysis revealed that relative to a nontargeting control, shRNA oligonucleotides that target 
the MMP9 (MMP9 eRNA-1) and CCL2 (CCL2 eRNA-1) eRNAs revealed a significant and 
specific decrease in the TNF-α-induced levels of MMP9 and CCL2 eRNAs by approximately 
three-fold and six-fold, respectively (Fig. 5a). Notably, this decrease in MMP9 and CCL2 
eRNA levels resulted in a significant (~three-fold) decrease in the MMP9 and CCL2 mRNA 
expression levels, respectively, thereby revealing a direct role for these TNF-α-induced 
eRNAs in the induction of proinflammatory gene expression (Fig. 5a). This reduction in the 
TNF-α-induced mRNA levels of MMP9 and CCL2 was further confirmed with a second 
shRNA oligonucleotide targeting different regions of the MMP9 (MMP9 eRNA-2) and CCL2 
eRNAs (CCL2 eRNA-2) (Supplementary Fig. 4a). In addition, and consistent with the 
specificity of the eRNA knockdown effects, shRNA-mediated knockdown of the MMP9 and 
CCL2 eRNAs did not affect the eRNA and mRNA expression levels of CCL2 and MMP9, 
respectively (Fig. 5a and Supplementary Fig. 4a) or that of CPA4 and CYP24A1 that are also 
significantly induced following TNF-α treatment (Supplementary Fig. 4b). Also, the gene-
selective effects of the MMP9 and CCL2 eRNAs are not due to altered mutp53 or BRD4 
protein levels, which were found to be unaffected by immunoblot analysis of whole cell 
lysates prepared from the eRNA knockdown cell lines (Fig. 5b). These results demonstrate 
the importance of the MMP9 and CCL2 eRNAs in regulating TNF-α-induced gene 
expression.  
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Having established significant knockdown of the MMP9 and CCL2 eRNAs, we next 
performed ChIP-qPCR in TNF-α-treated MMP9 and CCL2 eRNA knockdown cells to 
examine a direct role for these eRNAs in the regulation of BRD4 enhancer occupancy. 
Notably, BRD4 binding in the MMP9 and CCL2 eRNA-depleted cells was significantly and 
comparably (46% and 49%) reduced at the MMP9 and CCL2 enhancer regions, respectively 
(Fig. 5c). Notably, and consistent with the specificity of eRNA function, MMP9 eRNA 
knockdown did not affect BRD4 binding at the CCL2 enhancer region and vice versa (Fig. 
5c). This significant loss of BRD4 binding upon eRNA knockdown resulted in a significant 
and comparable (54% and 66%) decrease in RNAPII binding at the MMP9 and CCL2 
enhancers, respectively (Fig. 5c), which is consistent with the previously described roles of 
BRD4 in supporting RNAPII binding and elongation34,35. Moreover, we also tested the role of 
RNAs in the regulation of BRD4 enhancer binding by treating SW480 cells with 
Actinomycin D (Act D) that inhibits transcription, but does not affect BRD4 protein levels 
(Supplementary Fig. 4c). The significant decrease in the TNF-α-induced MMP9 and CCL2 
eRNA expression levels following Act D treatment (Supplementary Fig. 4d) was 
accompanied by a significant decrease in TNF-α-induced BRD4 binding by 61% and 77%, at 
the MMP9 and CCL2 enhancers, respectively (Supplementary Fig. 4e). These findings 
together with our eRNA knockdown analyses demonstrate a role for RNAs in regulating 
BRD4 enhancer recruitment in response to TNF-α signaling.  
Having demonstrated that eRNAs facilitate enhanced BRD4 binding to acetylated 
histones in vitro and at active enhancers with high levels of H3K27ac accumulation, we next 
investigated the effects of eRNAs on BRD4-dependent regulation of TNF-α-inducible eRNA 
and mRNA expression levels. ShRNA-resistant constructs expressing BRD4 FL or BRD4 
ΔBD1/2 were transiently expressed in SW480 cells cotransduced with lentiviral shRNA 
specific for MMP9 or CCL2 eRNA and BRD4. Relative to the vector control, both BRD4 FL 
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and BRD4 ΔBD1/2 equivalently reconstituted BRD4 mRNA and protein levels in BRD4 
knockdown cells (Fig. 5d). As expected, BRD4 FL, but not BRD4 ΔBD1/2 was able to fully 
rescue TNF-α-inducible MMP9 and CCL2 eRNA and mRNA expression levels in the BRD4 
single knockdown cells (Fig. 5e). Notably however, the ability of BRD4 FL to rescue CCL2 
eRNA and mRNA expression levels in the double CCL2 eRNA and BRD4 knockdown cell 
lines was significantly (2 to 3-fold) less efficient. Moreover, we observed that  BRD4 FL was 
comparably (2- to 3-fold) less efficient in rescuing MMP9 eRNA and mRNA levels in the 
BRD4 and MMP9 knockdown cells (Fig. 5e). In addition, BRD4 ΔBD1/2 was unable to 
rescue the reduced expression of MMP9 and CCL2 eRNA and mRNA levels in the MMP9 
and CCL2 eRNA/BRD4 double knockdown cells, respectively (Fig. 5e). These rescue 
experiments confirm the specificity of our BRD4 knockdown experiments and, taken 
together with our in vitro analyses, demonstrate that eRNAs play a pivotal role in regulating 
BRD4 enhancer binding that is required to support BRD4-dependent regulation of enhancer 
transcription and gene activation in response to chronic TNF-α signaling.  
Discussion 
BRD4 regulates a class of mutp53 enhancers and target genes in response to chronic 
immune signaling 
Enhancers are regulatory hubs that are selectively recognized by an array of transcription 
factors and co-activators that coordinate enhancer regulation of gene expression1,2. BRD4 is a 
well-known transcriptional coactivator that localizes at enhancers, especially clusters of 
enhancers (super enhancers) to regulate the transcription of the oncogenes, MYC and BCL2, 
which have important implications in human diseases that include, but are not limited to 
leukemia, multiple myeloma, and Burkitt lymphoma19-21,52,53. Our studies advance our 
understanding of BRD4’s role in human cancer through the identification of the genome-
wide binding of this coactivator at enhancers that are co-occupied by the potent oncogene 
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mutp53 that is known to drive aberrant gene expression in more than 50% of all human 
cancers. Notably, among the enhancers co-bound by mutp53 and BRD4 are several enhancers 
that have recently been shown to be regulated by mutp53 and NFκB and are linked to the 
potent activation of a proinflammatory gene expression program that leads to increased colon 
cancer cell growth and invasion potential48. In support of a functional relationship between 
mutp53 and BRD4, we found that purified BRD4 forms both direct interactions and 
physiological associations with mutp53 and is simultaneously bound with mutp53 at active 
enhancers in response to chronic TNF-α signaling. Furthermore, we demonstrated that 
mutp53 contributes to the recruitment of BRD4 at a subset of enhancers following chronic 
immune signaling. Our data also support the a role for BRD4 in regulating the activation of 
mutp53 and BRD4 co-bound enhancers as demonstrated by the significant decrease in TNF-
α-induced eRNA levels following BRD4 shRNA-mediated knockdown or inhibition by JQ1 
and the significantly higher eRNA levels found at BRD4 and mutp53 co-bound enhancers 
versus enhancers that are devoid of both BRD4 and mutp53. These findings that support a 
role for BRD4 in promoting the activation of mutp53 target genes by modulating enhancer 
activation in response to chronic immune signaling underscore the significance for mutp53 
and BRD4 cooperativity in colon cancer cells. Our findings reported here and future studies 
testing the roles of BRD4 in regulating mutp53-dependent gene expression programs are also 
likely to have clinical significance given the widespread roles of mutp53 and BRD4 in cancer 
and due to the potential for pharmacological inhibition of BRD4 through the targeting of 
small molecules including JQ1.  
eRNAs interact with BRD4 to affect transcriptional activation 
Given the prevalence of eRNAs in various cell types and in response to stimuli39-41,48,54-60, a 
number of functions for eRNAs in transcription can be envisioned. For example, it has been 
demonstrated that eRNAs interact directly with the transcriptional coactivator, Mediator41,43. 
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In addition, eRNAs function by promoting the chromatin modifying activities of the histone 
acetyltransferase CBP44 and by promoting chromatin accessibility through currently unknown 
mechanisms41. One possibility for how eRNAs could affect chromatin accessibility at 
enhancers may include direct effects on the SWI/SNF chromatin remodeler subunits BRG1 
and BRD7, which is supported by our finding that the BDs of BRG1 and BRD7 directly 
interact with eRNAs in this study. Overall, our results provide strong evidence for the 
functional significance of eRNAs in stimulating transcription by enhancing BRD4 binding to 
acetylated histones. Specifically, we demonstrate that eRNAs form physiological associations 
and direct interactions with the tandem bromodomains of BRD4, which in turn promotes 
enhanced BRD4 binding to acetylated forms of both histone H3 and H4 peptides as well as 
acetylated histone octamers. Our biochemical and biophysical findings are corroborated by 
our cell-based findings that show the importance of eRNAs in regulating the enhancer 
binding of BRD4. Strikingly, the depletion of TNF-α-inducible eRNA levels results in a 
significant decrease in the enhancer binding of BRD4, which in turn leads to a significant 
loss of RNAPII occupancy and a significant decrease in inflammation-induced gene 
expression in human colon cancer cells. Our studies also underscore the significance of 
BRD4-eRNA interactions in regulating enhancer-dependent gene activation by revealing the 
recovery of eRNA and tumor promoting gene expression by shRNA resistant BRD4 FL, but 
not BRD4 ΔBD in BRD4 single knockdown but not BRD4 and eRNA double knockdown 
cells. Taken together, our studies reported here, support a model (Fig. 6) for a positive 
feedback loop in which eRNAs could be involved in the cis recruitment of BRD4 at mutp53 
bound enhancers for augmented enhancer and gene activation. Furthermore, this model 
supports the functional interplay between histone modifications and eRNAs, which 
emphasizes that eRNAs are not required for the initial recruitment of BRD4 but rather 
cooperatively impact its binding potential after BRD4 has bound to acetylated histones. This 
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cooperativity between epigenetic mechanisms as revealed by our data showing that the 
acetyl-lysine recognition BDs interact with eRNAs together with previous studies showing 
that the methyl-lysine recognition chromodomain of CBX7CD binds lncRNA ANRIL61, 
suggest that eRNAs, similar to lncRNAs are likely to function through chromatin effector 
domains to impact chromatin and gene regulation. Importantly, our studies did not rule out 
whether other known BRD4 functional activities including its atypical histone modifying 
activity62 are affected by eRNAs. 
We demonstrate that BRD4 binds a broad spectrum of RNA transcripts, which 
suggests its promiscuous relationship with RNAs. Although RNA sequence does not appear 
to contribute to the specificity of BRD4-RNA interactions, and while we cannot rule out 
structural contributions of RNA from our analyses, we have found that BRD4 forms 
associations with RNAs in an enhancer/locus-specific manner. These results are supported by 
our BRD4 UV-RIP, BRD4 ChIP-seq, and GRO-seq analyses that together demonstrate the 
identification that BRD4 forms associations with RNAs that are produced specifically from 
genomic regions that are also highly occupied by BRD4 following chronic TNF-α signaling. 
This observation is consistent with a recent study showing that CBP also associates with 
RNAs that are produced at genomic regions where there exists high levels of CBP bound44. 
Our findings further demonstrate that shRNA-resistant BRD4 FL was able to reconstitute the 
expression levels of specific eRNAs in BRD4-depleted cells but not in BRD4 and eRNA-
double knockdown cells. Specifically, we show that the ability of BRD4 to reconstitute 
MMP9 and CCL2 eRNA levels occurs in the CCL2 and MMP9, but not the MMP9 and CCL2 
eRNA double knockdown cells, respectively, which is further consistent with enhancer/locus-
specific eRNA-BRD4 associations.  
eRNAs interact with the highly conserved acetyl-lysine recognition bromodomain 
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Our identification of this unexpected mechanism of eRNA function in regulating the 
chromatin binding and transcriptional coactivator functions of BRD4 could be widespread 
given that BDs are evolutionarily conserved protein interacting modules12 and were mapped 
in this study as the eRNA-interacting domains of BRD4. In support of the generality of this 
finding, we identified that the tandem BDs of all BET family members that include BRD2, 
BRD3, BRD4, and BRDT, and the single BD-containing, non-BET proteins, BRG1 and 
BRD7 form interactions with eRNAs. These results further demonstrated that while the RNA 
associations of the BRG1 and BRDT BDs are significantly above background, they are 
weaker relative to the BD-RNA interactions of BRD2, BRD3, BRD4, and BRD7. This 
variable level of RNA binding to various BDs is consistent with known differences in BD 
structure and conformation, which have been linked to disparities in the interactions of 
various BDs with acetylated residues in histones and other proteins and diverse roles in 
regulating transcription63. Moreover, given the development of inhibitors that are specific to 
the BDs of various members of the BET family and that have shown promising results in 
regulating gene expression in disease, particularly in cancer64, eRNAs that bind to BDs could 
be potent therapeutic targets to repress pro-tumorigenic gene expression programs.  
Our observation that eRNAs through BD interactions enhance BRD4 binding to 
acetylated histones and octamers suggest that eRNAs are likely to interact with the BD in a 
region that is independent of the acetyl lysine-recognition domain. While BDs are 
categorized into eight distinct classes based on their diverse structures, they share four 
conserved α-helices that are connected to one another by loops of variable lengths15,63. 
Conserved amino acids located within these loops facilitate the docking of acetylated lysine 
residues and the surface that surrounds the acetyl binding pocket is often comprised of a 
patch of basic amino acids that have been shown to further prompt interactions with the 
backbone of acetylated substrates11,63. It is possible that this positively charged surface found 
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in BDs could also facilitate interactions with negatively charged nucleic acids, including 
eRNAs. This possibility is consistent with recent studies that have shown that this positively 
charged patch facilitates interactions of the BRDT BD165 and more recently the 
BRG1/hBRM BDs66 with DNA that in turn, facilitate acetylation-dependent nucleosome 
binding of these BD-containing proteins65,66. Furthermore, point mutations in the positively 
charged patch within the hBRM BD were found to significantly reduce hBRM’s binding to 
DNA, while not disrupting BD interactions with H3K14 acetylated peptides66. This finding 
suggests that BD interactions with nucleic acids are likely to occur outside the region that is 
required for acetyl-lysine recognition and thereby could allow for RNA/DNA interactions 
that enhance BD association with acetyl-lysines. In addition, differences in the number of 
basic amino acids within the BD loops could contribute to variations in the electrostatic 
charge that together with variable structural/conformational contributions and other potential 
regulatory mechanisms, may predict the variable levels of interaction that we observed 
between eRNAs and different BDs assessed in our study. Furthermore, these variations could 
also explain the differences in BD interactions with DNA versus that of RNA. Specifically, 
the analyses of BRD4 interactions with DNA revealed that DNA associations occur only with 
the BRD4 BD2 and not BD165. In comparison, we found that BRD4 BD1 and BD2 interact 
with eRNAs weakly and that the tandem BDs of BRD4 are required to support eRNA 
interactions that are comparable to the naturally occurring, shorter isoform of BRD4 (BRD4 
1-722). Future studies are needed to determine the functional importance of BD contacts with 
DNA versus RNA and the differential regulatory mechanisms that govern these BD 
interactions.  
Our demonstration that each of the tandem BRD4 BDs (BD1 and BD2) are required 
to reconstitute BRD4 interactions with eRNAs, together with our data demonstrating the 
significance of bivalent interactions of BDs with acetylated lysines and eRNAs is consistent 
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with previous reports revealing the importance of multivalency in chromatin regulation. 
Specifically, the overall affinity and specificity of chromatin binding can be significantly 
enhanced by multiple chromatin interacting domains within a single chromatin reader or 
through the multiple chromatin interacting proteins that are often present in multiprotein 
complexes67. Consistent, is the identification that the BDs of the BET family exhibit modest 
affinity for monoacetylated lysine, however the affinity of their binding is significantly 
increased when the BDs are anchored to multiple acetylation sites11,14,51. Future studies are 
needed to extend the implications of BD-RNA interactions and test how BDs engage these 
epigenetic modifiers to transduce downstream function. 
Taken together, our findings are consistent with the emerging notion that eRNAs are 
functional molecules, rather than merely reflections of enhancer activation or simply 
transcriptional noise. Our studies provide mechanistic insights into the role of enhancer 
transcripts that directly interact with BRD4 at active enhancers, which leads to increased 
RNAPII binding, eRNA synthesis, and the transcription of proinflammatory genes. These 
findings provide a framework for understanding eRNAs and their convergence with histone 
modifications in the regulation of transcriptional coactivators.  
METHODS 
Cell culture and treatments Human colorectal adenocarcinoma SW480 cells and human 
embryonic kidney 293T (HEK293T) cells were purchased from American Type Culture 
Collection (ATCC) and grown in Dulbecco’s modified Eagle medium (DMEM, Gibco) 
supplemented with 10% fetal bovine serum (FBS, Gibco). SW480 cells that stably and 
inducibly express short hairpins against LacZ or p53 were kindly provided by Xinbin Chen 
(UC Davis) and were grown in standard DMEM medium containing penicillin and 
streptomycin (Gemini Bio-Products), 1.5 µg ml-1 puromycin (Sigma), and were induced with 
1 µg ml-1 doxycycline (Sigma). Lentivirus infected SW480 cells were propagated in growth 
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medium containing DMEM, 10% FBS, 100 units ml-1 penicillin, 100 µg ml-1 streptomycin, 
and 1.5 µg ml-1 puromycin. For experiments with TNF-α treatment, the indicated cells were 
treated with 12.5 ng ml-1 recombinant TNF-α (Shenandoah Biotechnology) for the indicated 
time points before harvesting for gene expression or ChIP analyses. SW480 cells were treated 
with a final concentration of 500 nM JQ1 (Cayman Chemical) or vehicle (DMSO, Fisher 
Scientific) before harvesting for gene expression and immunoblot analyses. All cell lines 
mentioned have tested negative for mycoplasma contamination by PCR.  
Immunoblotting Protein samples were incubated at 95 °C for 5 min, separated by SDS-
PAGE, and transferred to PVDF membranes (EMD Millipore) that were probed with the 
indicated antibodies. Reactive bands were detected by ECL (Thermo Scientific Pierce), and 
exposed to Blue Devil Lite ECL films (Genesee Scientific) or visualized by LI-COR (LI-
COR Biosciences).  
Antibodies Antibodies used for ChIP assays were obtained commercially as follows: anti-
BRD4 (A301-985A100, 1 µg) from Bethyl laboratories; anti-RNAPII (N20, sc899, 1 µg), 
anti-IgG (sc2027, 1 µg) from Santa Cruz Biotechnology. Antibodies used for immunoblotting 
were obtained as follows: anti-BRD4 (1:3000 dilution) from Bethyl laboratories, anti-H3 
(ab1791, 1:5000 dilution), anti-H3K27ac (ab4729, 1:5000 dilution) from Abcam; anti-
H3K9ac (13-0020, 1:5000 dilution) from EpiCypher; and anti-p53 (DO1, sc126, 1:2000 
dilution) and anti-β-Actin (sc47778, 1:2000 dilution) from Santa Cruz Biotechnology.  
Lentivirus production and transduction pLKO.1 TRC control and target shRNA plasmids 
were generated with annealed primers to knockdown BRD4 and MMP9 and CCL2 eRNAs. 
shRNA primers used in this study are listed in Supplementary Table 1. For lentivirus 
production and transduction, 50-60% confluent HEK293T cells were transfected with 
Lipofectamine 3000 (Invitrogen) with TRC control, target shRNAs, and packaging plasmids 
psPAX2 and pMD2.G. Virus-containing medium was collected 48 and 72 hr post 
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transfection, filtered with a 0.45µm pore size filter, and used for viral infection. SW480 cells 
were transduced with the viral supernatants containing 8 µg ml-1 polybrene (Sigma-Aldrich). 
After 8 hr infection, virus-containing medium was removed and replaced with fresh medium. 
After 48 hr, puromycin was added to a final concentration of 1.5 µg ml-1. Cells were cultured 
for an additional 72 hr before harvesting the cells for qRT-PCR and immunoblot to confirm 
successful knockdown efficiency. 
In vitro RNA synthesis Primers were designed to amplify desired genomic regions that 
correspond to maximal eRNA (GRO-seq) peaks at MMP9 and CCL2 enhancers and MEG3 
and p21 exonic sequences. Primers sequences can be found in Supplementary Table 5. The 
T7 promoter sequence was included in the forward primer and genomic fragments were PCR 
amplified from HeLa genomic DNA (NEB), confirmed by sequencing, and subsequently 
used for RNA synthesis using T7 RiboMAX Express Large Scale RNA Production System 
(Promega). Synthesized RNAs were purified per manufacturer’s instructions and quantitated 
by Nanodrop (Invitrogen). RNA probes were refolded by incubation at 95 ºC for 5 min 
followed by snap-cooling on ice for 5 min. Cold RNA refolding buffer (10 mM Tris-HCl at 
pH 7, 100 mM KCl, 10 mM MgCl2) was then added and the samples were transferred to an 
ice-cold metal rack. RNAs were allowed to refold by warming the sample to room 
temperature for 20-30 min. 
RNA purification and quantitative real-time PCR Total RNA was extracted with TRIzol 
LS reagent (Invitrogen) from SW480 stably expressing control, BRD4, or CCL2 and MMP9 
eRNA shRNAs and treated with 12.5 ng ml-1 TNF-α for the indicated time points. Total 
RNA (0.5-1 µg) was used for cDNA synthesis using ProtoScript II First Strand cDNA 
Synthesis Kit (NEB) with random hexamers. PCR reactions were performed on an Applied 
Biosystems Step One Plus real-time PCR systems using SYBR Green PCR Master Mix 
(Applied Biosystems) in duplicate using samples from at least three independent cell harvests 
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and the specificity of amplification was examined by melting curve analysis. The relative 
levels of eRNA and mRNA expression were calculated according to the (ΔΔCt) method and 
individual expression data was normalized to GAPDH. The gene expression levels 
determined after TNF-α treatment are relative to the levels before TNF-α treatment. Primers 
for qRT-PCR are listed in Supplementary Table 2. 
Ultraviolet-RNA Immunoprecipitation (UV-RIP) SW480 cells treated with TNF-α for 0 
or 16 hr were crosslinked by UV irradiation (150 mJ per cm2 at 254 nm) using a Stratalinker 
and lysed in RIP lysis buffer [25 mM HEPES-KOH at pH 7.5, 150 mM KCl, 0.5% NP40, 1.5 
mM MgCl2, 10% glycerol, 1 mM EDTA, 0.05% NP40, 0.4 U RNase inhibitor (Promega), 
protease inhibitor cocktails (PICs)] on ice for 30 min. Cleared cell lysates were used for IP 
with BRD4 and IgG-antibody bound Protein A Dynabeads (Invitrogen) overnight. Beads 
were subsequently washed three times with RIP lysis buffer and RNA samples were eluted 
using TRIzol LS reagent. cDNA samples were prepared as described above and analyzed by 
qRT-PCR primers listed in Supplementary Table 2.  
Histone peptide binding assays Unmodified H3 (21-44), K27ac-modified H3 (21-44), 
unmodified H4 (1-25), or K16ac-modified H4 (1-25) peptides (Innopep Inc.) were 
immobilized on Dynabeads MyOne Streptavidin C1 (Life technologies) and subsequently 
incubated with 200 ng of recombinant FLAG-BRD4 FL or FLAG-BRD4 𝛥BD1/2 in the 
absence or presence of 0.2 nM refolded MMP9 or CCL2 eRNA in binding buffer (150 mM 
NaCl, 20 mM HEPES-KOH at pH 7.9, 0.1% NP40, 0.25 mg ml-1 bovine serum albumin 
(BSA), 1 mM Sodium butyrate, 1mM PMSF, PICs, RNase inhibitor) for 4 hr at 4°C. Beads 
were washed ten times with binding buffer containing 400 mM NaCl. Bound proteins were 
eluted in sample buffer and analyzed by SDS-PAGE and immunoblotting. 
Histone acetyltransferase (HAT) assays Recombinant histone octamers (0.5 µg) that were 
purified as previously described68 were incubated with p300 (30 ng) and acetyl-CoA (20 µM) 
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in reaction buffer (50 mM HEPES pH 7.8, 30 mM KCl, 0.25 mM EDTA, 5.0 mM MgCl2, 
5.0 mM sodium butyrate, 2.5 mM DTT). Reactions were incubated at 30˚C for 30 min, 
resolved by SDS-PAGE, and analyzed by immunoblotting.  
Histone octamer binding assays p300-acetylated histone octamers were isolated by 
incubating the HAT reactions with H3K9ac and H3K27ac antibody-coupled Protein A 
Dynabeads in binding buffer (150 mM NaCl, 50 mM Tris-HCl at pH 8.0, 0.1% NP40, 1 mM 
Sodium butyrate, 1 mM PMSF, PICs) for 3 hr at 4 ºC. Following the incubation, the 
acetylated histone octamer bound beads were washed three times with binding buffer and 
then incubated with 200 ng of recombinant FLAG-BRD4 FL or FLAG-BRD4 𝛥BD1/2 in the 
absence or presence of 0.2 nM refolded eRNA or increasing doses in the range of 0.06 nM to 
2 nM in binding buffer with 1% BSA for 12 hr at 4 ºC. The protein complexes were washed 
eight times with wash buffer (400 mM NaCl, 50 mM Tris-HCl at pH 8.0, 0.1% NP40, 0.5% 
BSA, 1 mM Sodium butyrate, 1 mM PMSF, PICs). Bound proteins were eluted in sample 
buffer and analyzed by SDS-PAGE and immunoblotting with the indicated antibodies. 
Surface plasmon resonance (SPR) assays Sensorgrams were recorded on a BIAcore 3000 
instrument using streptavidin (SA) chips. Biotinylated H3K27ac histone peptide was 
immobilized on the SA chip in binding buffer (150 mM NaCl, 20 mM HEPES-KOH at pH 
7.9, 0.1% NP40). Sensorgrams were run in the automatic subtraction mode using flow cell 1 
(FC 1) as an unmodified reference. Data was collected for FC's 2, 3, and 4, which contained 
varying amounts of the BD1/2 domain of BRD4 and in the presence or absence of 0.2 nM 
refolded MMP9 eRNA with 100 Response Units (RU) immobilized on FC2, 200 RU on FC3, 
and 400 RU on FC4. Injections were made using the kinject injection mode with a 3 min 
contact time and a 3 min dissociation phase, at a flow rate of 50 µl min-1. The running buffer 
used for the binding experiments was 150 mM NaCl, 20 mM HEPES-KOH at pH 7.9, 0.1% 
NP40. The data was analyzed using the BIA Evaluation 4.1 software. 
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Co-immunoprecipitation Assays were performed using whole cell lysates prepared from 
SW480 cells that were treated with 12.5 ng ml-1 TNF-α for 0 or 16 hr. Cleared lysates were 
first incubated with indicated antibodies for 2 hr at 4 ºC followed by an additional 2 hr 
incubation with Protein A Sepharose (Rockland Inc.). Beads were washed with wash buffer 
(20 mM Tris-HCl at pH 7.9, 0.1% NP40, 150 mM KCl) five times and analyzed by 
immunoblotting. 
Chromatin Immunoprecipitation (ChIP) and ChIP-Seq BRD4 ChIP assays were 
performed using SW480 cells that were (i) untreated or treated with 12.5 ng ml-1 TNF-α for 
the indicated time points or (ii) transduced with indicated shRNAs and treated with 12.5 ng 
ml-1 TNF-α for 0 or 16 hr. Cells were sequentially cross-linked using 6 mM DSG 
(disuccinimidyl glutarate; ProteoChem) for 30 min and a final concentration of 1% 
formaldehyde for 10 min at room temperature and stopped with 125 mM glycine (Fisher 
Scientific). Cells were lysed in lysis buffer (20 mM Tris-HCl at pH 7.5, 300 mM NaCl, 2 mM 
EDTA, 0.5% NP40, 1% Triton X-100, 1 mM PMSF, PICs) and incubated on ice for 30 min. 
The resuspended cells were then dounced in an ice-cold homogenizer. Nuclear pellets were 
collected and resuspended in shearing buffer (0.1% SDS, 0.5% N-lauroylsarcosine, 1% 
Triton X-100, 10 mM Tris-HCl at pH 8.1, 100 mM NaCl, 1 mM EDTA, 1 mM PMSF, PICs). 
Isolated chromatin was fragmented to an average size of 200-600 bp with a bioruptor Pico 
(Diagenode). Precleared chromatin was immunoprecipitated overnight at 4 ºC and 
immunocomplexes were collected with protein A Dynabeads. The immunocomplexes were 
washed eight times in wash buffer (50 mM HEPES-KOH at pH 7.6, 500 mM LiCl, 1 mM 
EDTA, 1% NP40, 0.7% sodium deoxycholate, 1 mM PMSF, PICs), followed by two 1X TE 
washes, and eluted in elution buffer (50 mM Tris-HCl at pH 8.0, 10 mM EDTA, 1% SDS), 
crosslinks were reversed at 65 ºC for 4 hr or overnight, and DNA was purified using DNA 
Clean & Concentrator Kit according to the manufacturer’s instructions. PCR reactions were 
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performed on an Applied Biosystems Step One Plus real-time PCR systems using SYBR 
Green PCR Master Mix in duplicate using samples from at least three independent cell 
harvests and the specificity of amplification was examined by melting curve analysis. The 
relative amounts of ChIP DNA were quantified relative to inputs. Primers for ChIP-
quantitative PCR are listed in Supplementary Table 3. Sequential ChIP experiments were 
performed exactly as described above with minor modifications. Specifically, 150 µg of 
sheared chromatin was used to perform the IP. Following the washes after the first IP, 
immunocomplexes were eluted in re-IP elution buffer (50 mM Tris-HCl at pH 8.0, 1% SDS, 
1 mM EDTA, 1 mM DTT, 1 mM PMSF, PICs) and diluted 10 fold in dilution buffer (16.7 
mM Tris-HCl at pH 8.0, 167 mM NaCl, 0.01% SDS, 1% Triton X-100, 1.2 mM EDTA, 1 
mM PMSF, PICs). The second IP was performed with indicated antibodies overnight at 4 ºC, 
followed by additional washes and the final elution as described above. 
For ChIP-seq experiments, the IP’s were performed as described. The eluted ChIP 
DNA was quantified using a Qubit 2.0 fluorometer (Invitrogen), and 2-5 ng of ChIP DNA 
was used to prepare the sequencing libraries from two biological replicates using the TruSeq 
ChIP Sample Prep Kit according to the manufacturer's instructions (Illumina). Briefly, ChIP 
DNA was end-repaired and adaptors were ligated to the ends of the DNA fragments. 
Adaptor-ligated ChIP DNA fragments with average size of 350 bp were used to construct 
libraries and single-end sequenced (50 bp) on Illumina HiSeq 4000. Sequencing reads were 
mapped to the hg38 human genome using Bowtie2 software 38 and default parameters. The 
mapped reads were then processed to make Tag Directory module using HOMER for 
filtering. Briefly, PCR duplications were removed and only uniquely mapped reads were kept 
for further analysis. The genome browser files for the resulting reads were generated by using 
make UCSC file module from HOMER. Enriched regions for BRD4 were called using find 
Peaks module from HOMER by using preset options, factor or histone styles respectively and 
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compared to the corresponding inputs. Deeptools were used to generate heat maps. De novo 
motif analysis was performed using the BRD4/mutp53 co-bound enhancer regions using 
“findMotifsGenome.pl” of Homer with ±100 bp window relative to the peak center. 
Purification of recombinant proteins Mutant p53 R273H was generated by site-directed 
mutagenesis (Agilent Technologies). FLAG-BRD4 BD1/2, BD1, BD2 were cloned into 
pET11d bacteria expression vector using NdeI and BamHI sites after amplification from 
BRD4 cDNA. His-tagged tandem BDs (BD1/2) of BRD2, BRD3, BRD4, and BRDT as well 
as the single BDs of BRG1 and BRD7 were cloned into pET 6His bacteria expression vector 
using BamHI and EcoRI sites. p53 and BD constructs were expressed in E. Coli and purified 
on FLAG M2 agarose beads (Sigma) or TALON metal affinity resin (Clontech). The FLAG 
BRD4 FL and ΔBD1/2 proteins were expressed in Sf9 cells and purified on FLAG M2 
agarose. Primers used for cloning are listed in Supplementary Table 4.  
In vitro pull-down RNA binding assays FLAG- and His-tagged proteins were incubated 
with 500 ng of refolded RNA while rotating at 4 ºC for 1 hr in RNA Binding Buffer (20 mM 
Tris-HCl at pH 7.4, 100 mM KCl, 0.2 mM EDTA, 0.05% NP40, 0.4 U RNase inhibitor, 
PICs). Protein-RNA complexes were recovered using FLAG M2 agarose beads or TALON 
resin for 1 hr at 4 ºC. Beads were washed three times with RNA wash buffer (20 mM Tris-
HCl at pH 7.4, 200 mM KCl, 0.2 mM EDTA, 0.05% NP40, 0.4 U RNase inhibitor, PICs) and 
RNA samples were eluted using Trizol LS reagent. Purified RNA samples were resolved on a 
denaturing 5% TBE urea gel and stained with SYBR gold for 30 min before imaging using a 
Typhoon phosphorimager or LI-COR (LI-COR Biosciences).  
RNA electrophoretic mobility shift assay (EMSA) EMSAs were performed following 
established protocols69. Binding reactions were performed in 1x RNA EMSA buffer (20 mM 
Tris-HCl at pH 7.4, 100 mM KCl, 1 mM EDTA, 1% glycerol, 0.05% NP40, 0.5 mM ZnCl2, 
0.1 mg ml-1 BSA (Fisher), 0.1 mg ml-1 yeast tRNA (Sigma), 2 mM DTT, 0.4 U RNase 
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inhibitor). The binding reactions were initiated by adding different doses (0.3-1.5 µg) of 
FLAG-BRD4 protein in the presence of 12,000 cpm refolded RNA and allowed to proceed 
for 30 min at 4 ºC. Reactions were loaded immediately on 6% Native polyacrylamide gels 
that was pre-run for 1 hr at 100V in 0.5X TBE at 4 ºC. The gel was run for 4 hr at 100V and 
exposed to autoradiography screen before imaging with Typhoon phosphorimager. For 
competition assays, (0, 50, 150, or 450 nM) of unlabeled RNA or ssDNA was added in 
addition to the 32P radiolabeled RNA.  
Data availability All sequencing data that support the findings of this study will be deposited 
in the National Center for Biotechnology Information Gene Expression Omnibus (GEO) and 
will be accessible through the GEO Series upon acceptance. All other relevant data are 
available from the corresponding author upon reasonable request. 
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Supplementary Tables  
Supplementary Table 1. shRNA targeting sequences, related to experimental 
procedures 
Name Sequence 
shMMP9 eRNA-1 F 
CCGGGGCTTAGAGTCTAAGCTATCTGCAGATAGCT
TAGACTCTAAGCCTT TTTG 
shMMP9 eRNA-1 R 
AATTCAAAAAGGCTTAGAGTCTAAGCTATCTGCAG
ATAGCTTAGACTCTA AGCC 
shMMP9 eRNA-2 F 
CCGGTACGTGAGGGTATATGCTGTTCTCGAGAACA
GCATATACCCTCACG TATTTTTG 
shMMP9 eRNA-2 R 
AATTCAAAAATACGTGAGGGTATATGCTGTTCTCG
AGAACAGCATATACC CTCACGTA 
shCCL2 eRNA-1 F 
CCGGCCAACACTCAGAAGCCTATCTGCAGATAGGC
TTCTGAGTGTTGGTTTTTG 
shCCL2 eRNA-1 R 
AATTCAAAAACCAACACTCAGAAGCCTATCTGCAG
ATAGGCTTCTGAGTGTTGG 
shCCL2 eRNA-2 F 
CCGGCCACCAAGTTCATGGTAAACTGCAGTTTACC
ATGAACTTGGTGGTTTTTG 
shCCL2 eRNA-2 R 
AATTCAAAAACCACCAAGTTCATGGTAAACTGCAG
TTTACCATGAACTTGGTGG 
shBRD4-1 (3'UTR) F 
CCGGCACGCCTTGTTACGAGCAAGTCTCGAGACTT
GCTCGTAACAAGGCGTGTTTTTG 
shBRD4-1 (3'UTR) R 
AATTCAAAAACACGCCTTGTTACGAGCAAGTCTCG
AGACTTGCTCGTAACAAGGCGTG 
shBRD4-2 (exon) F 
CCGGAGCTGAACCTCCCTGATTACTCGAGTAATCA
GGGAGGTTCAGCTTTTTTG 
shBRD4-2 (exon) R 
AATTCAAAAAAGCTGAACCTCCCTGATTACTCGAG
TAATCAGGGAGGTTCAGCT 
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Supplementary Table 2. Oligonucleotide sequences for RT-PCR analysis of gene 
expression, related to the experimental procedures 
 
Name Sequence 
CSF2 eRNA-F CTGAAGCTGTGAGCAGAGAAA 
CSF2 eRNA-R CCAAGTAGCAGGAAGAGTGATG 
TNFAIP2 eRNA-F AGGCCAAGGAGGGAGTTATAG 
TNFAIP2 eRNA-R CCTCCATTGTTGAGCAGTAGTC 
MMP9 eRNA-F TGATGGAGCTACCTCAGTG 
MMP9 eRNA-R CCACAATAGAGTTTAGCCAAGA 
MMP9 mRNA-F GACCTGGGCAGATTCCAAA 
MMP9 mRNA-R GGCAAGTCTTCCGAGTAGTTT 
CCL2 eRNA-F TTTGTGCCAGAGCCTAACC 
CCL2 eRNA-R AGTTCCCAGATCCCGTAGAA 
CCL2 mRNA-F CAGCCAGATGCAATCAATGCC 
CCL2 mRNA-R TGGAATCCTGAACCCACTTCT 
CYP24A1 eRNA-F TACGCAGTCTTTGTGCAGTAG 
CYP24A1 eRNA-R GGAGGTTACATCGCTGTTCTC 
CYP24A1 mRNA-F GTACAGCGAACTGAACAAATGG 
CYP24A1 mRNA-R CTGGAGAAGCCCAAATCTCTT 
CPA4 eRNA-F TTCTTTCTCTGGGAGCTTTCC 
CPA4 eRNA-R GTTTGGAAGCTGGACCTATGA 
CPA4 mRNA-F CAACACAATGAAGGGCAAGAA 
CPA4 mRNA-R AGGAAAGTCTGCGGCAAT 
TFAP2A eRNA-F CGCCCAGAGAAGAATGTGTTA  
TFAP2A eRNA-R GAGAAGGTGGCTAGGTTAGAGA 
TFAP2A mRNA-F AACGTTACCCTGCTCACATC 
TFAP2A mRNA-R GAGAAATTCAGCTACTGCTTTGG 
MPP7 eRNA-F GCAGACTGGAGTGTGTTTCA 
MPP7 eRNA-R ATCGCAGCGGCTTAAGAAA 
MPP7 mRNA-F CATGTGGATAGCCAGGAAGAC 
MPP7 mRNA-R ACCGGACTCTGCTTCTCATA 
BRD4 mRNA-F AAGGAAAGAGGAAGTGGAAGAG 
BRD4 mRNA-R CACATTGCTGTTGCTGCTATTA  
GAPDH mRNA-F ATTTGGTCGTATTGGGCGCCTG 
GAPDH mRNA-R AGCCTTGACGGTGCCATGGAATTT 
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Supplementary Table 3. Oligonucleotide sequences for ChIP analyses, related to 
experimental procedures 
 
Name Sequence 
MMP9 -3.7kb enhancer-F CAGGGTCTTGGCTAAACTCTATT 
MMP9 -3.7kb enhancer-R TGGACAGAGCTTGGCTTTC 
MMP9 +2.4kb genic-F GATGGTCCTGGGTTCTAATTCC 
MMP9 +2.4kb genic-R GCAGTTCATCCCATCTCTCATC 
MMP9 +13kb -F CGCTCTTTCTCCCTCCTAGA 
MMP9 +13kb -R TCTGGGTCAGGGCTTCT 
CCL2 2.6kb enhancer-F TTTGTGCCAGAGCCTAACC 
CCL2 2.6kb enhancer-R AGTTCCCAGATCCCGTAGAA 
CCL2 +1.1kb genic-F CAAAGAAGCTGTGATGTGAGTTC 
CCL2 +1.1kb genic-R GCACTCTCTGACTCTAGGTTTATG 
CCL2 +6kb -F ATGTCTGCCCAGCAGTATATC 
CCL2 +6kb -R ACAAGGTGGAATAGGAACAAGA 
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Supplementary Table 4. Oligonucleotide sequences used for cloning, related to 
experimental procedures 
 
Name Sequence 
FLAG-BRD4-BD1-F GCGGCGTCATATGAGGCAGACCAACCAA 
FLAG-BRD4-BD1-R AAGGATCCCTAGGTTTCTTCTGTGGG 
FLAG-BRD4-BD2-F GCGGCGTCATATGAAGGTCTCGGAGCAG 
FLAG-BRD4-BD2-R GCGGATCCCTAAGGCTCGTCCGGCATCTT 
FLAG-BRD4-BD1/2-F GCGGCGTCATATGAGGCAGACCAACCAA 
FLAG-BRD4-BD1/2-R GCGGATCCCTAAGGCTCGTCCGGCATCTT 
His-BRD2 BD1/2-F AAGGATCCCGAGTTACCAACCAGC 
His-BRD2 BD1/2-R AGGAATTCCTATGGTTCATCTGGCAT 
His-BRD3 BD1/2-F AAGGATCCCGCAAGACCAACCAG 
His-BRD3 BD1/2-R AGGAATTCCTAGGGCTCATCTGGCAT 
His-BRD4 BD1/2-F AAGGATCCAGGCAGACCAACCAA 
His-BRD4 BD1/2-R AGGAATTCCTAAGGCTCGTCCGGCATCTT 
His-BRDT BD1/2-F CGGGATCCCGATTGACAAATCAACT 
His-BRDT BD1/2-R AGGAATTCCTAAGGTTCAATCGGGATC 
His-BRG1 BD-F AAGGATCCTCCCCTAACCCACCCA 
His-BRG1 BD-R AGGAATTCCTAACTGTCATCCTCCTT 
His-BRD7 BD-F CGGGATCCCAGAGAAAAGATCCAA 
His-BRD7 BD-R AGGAATTCCTAATAATAAATGGTCTCTGG 
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Supplementary Table 5. Oligonucleotide sequences for amplification of genomic regions 
corresponding to various RNA species used for in vitro RNA synthesis, related to 
experimental procedures 
 
Name Sequence 
MMP9 F ATGGATCCATTAATACGACTCACTATAGCCCTCTCTGGCAGGTTTGGG 
MMP9 R TTGGTACCGGGAGTGCAGGCAGAGAA 
CCL2 F CCGGTACCTAATACGACTCACTATAGCTTTATCTATGAGTTGATAG 
CCL2 R TTCTCGAGAGCTTTGGAAGTTCCCAG 
MEG3 F CCGGTACCTAATACGACTCACTATAGAGGGCACTAGGAGCACGGTT 
MEG3 R TTCTCGAGCTGATGCAAGGAGAGCCC 
p21 Exon2 F CGGGTACCTAATACGACTCACTATAGGCGCCATGTCAGAACCGGCT 
p21 Exon2 R ATCTCGAGCTGTCATGCTGGTCT 
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Figure 1. BRD4 co-occupies and regulates mutp53 bound enhancers in response to chronic TNF-α signaling. 
a, Heat maps of the BRD4 and p53 R273H binding sites at intergenic regions enriched for H3K27ac and H3K4me1 histone 
marks in SW480 cells that were treated with TNF-α for 16 hr. Each row shows ±1 kb centered on BRD4 peaks. b, (Top) 
schematics of ChIP-qPCR amplicons and (bottom) ChIP-qPCR analyses of IgG, p53 R273H, and BRD4 enrichment at the 
enhancer (amplicon A) and non-specific (amplicon B) regions of MMP9 and CCL2 gene loci in SW480 cells stably 
expressing LacZ (Ctrl) or p53 shRNA and treated with TNF-α for 16 hr. c, Boxplots showing log2 fold change in GRO-seq 
signal in response to TNF-α signaling at intergenic regions enriched for the H3K27ac histone mark that were co-bound or 
unbound by BRD4 and p53 R273H. d, qRT-PCR and immunoblot analysis of SW480 cells stably expressing control (Ctrl) 
or two different BRD4 shRNAs (BRD4-1, BRD4-2) and treated with TNF-α for 0 or 16 hr. e, ChIP-qPCR analysis of 
BRD4 binding in SW480 cells treated as described in (d) at enhancer (A) and non-specific (B) regions 
of MMP9 and CCL2 gene loci. For the ChIP-qPCR analyses in (b) and (e), the average of at least two independent 
experiments that are representative of three is shown with error bars denoting the standard error. f, qRT-PCR analyses of 
MMP9 and CCL2 eRNAs and mRNAs in SW480 cells treated as described in (d). The expression levels shown after TNF-
α are relative to the levels before treatment with the bar graphs representing the average of three independent experiments 
and error bars denoting the standard error. Statistical significance was determined by two-tailed Student’s t-test. * indicates 
p-value <0.05. 
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Figure 2. BRD4 associates with RNAs synthesized from genomic regions occupied by BRD4. 
a, UV-RIP qPCR analysis of the MMP9, CCL2, TFAP2A, and MPP7 eRNAs and b, mRNAs following IgG or BRD4 IP in 
SW480 cells treated with TNF-α for 0 or 16 hr. Enrichment levels for each TNF-α treated IP is relative to the levels before 
TNF-α treatment. The bar graphs represent the average of three independent UV-RIP experiments with the error bars 
denoting the standard error. Statistical significance was determined by two-tailed Student’s t-test. * indicates p-value 
<0.05. ns: no significance. c, UCSC genome browser images of GRO-seq and d, BRD4 ChIP-seq signals in SW480 cells 
treated as described in (a) at active enhancer regions and TSSs adjacent to the MMP9, CCL2, TFAP2A, and MPP7 gene 
loci.  
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Figure 3. BRD4 directly interacts with eRNAs through its tandem bromodomains. 
a, RNA EMSA performed with in vitro transcribed, 32P-labeled MMP9 eRNA and titrations of recombinant BRD4 
FL. b, (Left) competition binding RNA EMSAs in which binding of 32P-labeled MMP9 eRNA to 0.9 µg of BRD4 FL was 
competed with 50, 150, and 450 nM unlabeled CCL2 eRNA and MMP9 ssDNA. (Right) quantification of the fraction of 
RNA bound to BRD4 FL in the presence of unlabeled competitors as denoted, corresponding to the autoradiogram shown 
in the left panel. c, Schematic of BRD4 proteins expressed, purified, and used in RNA EMSA and in vitro RNA binding 
assays. d, f, In vitro pull-down of MMP9 and CCL2 eRNAs with the indicated FLAG-tagged BRD4 proteins and g, the 
His-tagged tandem BDs of BRD2, BRD3, BRD4, and BRDT and the single BDs of BRG1 and BRD7 as revealed by 
SYBR Gold staining and SDS-PAGE/coomassie staining analyses of the purified proteins. e, RNA EMSA performed with 
in vitro transcribed 32P-labeled MMP9 eRNA and titrations of recombinant BRD4 ΔBD1/2. One reaction with 1.2 µg of 
BRD4 FL was also performed as control and denoted with *. f, All RNA EMSAs and in vitro binding assays were 
performed three independent times with representative images for each assay shown in the corresponding panels. 
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Figure 4. eRNAs cooperate with acetylated histones to enhance BRD4 binding, in vitro. 
Immobilized peptide pulldown assay using biotinylated a, H3 peptides (unmodified or K27acetylated-modified) and b, H4 
peptides (unmodified or K16acetylated-modified) with either recombinant BRD4 FL or BRD4 𝛥BD1/2 in the absence or 
presence of refolded MMP9 eRNA as indicated. Recombinant BRD4 FL and BRD4 𝛥BD1/2 were detected by 
immunoblotting with an antibody specific to BRD4. c, Immunoblot analysis of in vitro binding assays with unacetylated or 
acetylated histone octamers, recombinant BRD4 FL or 𝛥BD1/2, and refolded MMP9 eRNA as indicated. Immunoblot 
analysis with H3K27ac and H3K9ac antibodies confirmed the p300- and acetyl-CoA-mediated acetylation of the histone 
octamers. Lower panels in (a), (b), and (c) represent the loading of the indicated proteins by coomassie staining. d, 
Analysis of BRD4 BD1/2 binding to immobilized, biotin-labeled H3K27ac peptides in the absence or presence of refolded 
MMP9 eRNA as measured in response unit (RU) by surface plasmon resonance. Representative sensorgrams were obtained 
from injections of 10, 15, and 20 nM of BRD4 BD1/2 with and without 0.2 nM of MMP9 eRNA in binding buffer for 300 s 
at 50 µl min-1. e, Rmax plot depicting the maximal binding capacity of BRD4 BD1/2 at various concentrations in the 
absence (black) and presence (red) of refolded MMP9 eRNA. All in vitro binding assays were performed three independent 
times with representative images for each assay shown in the corresponding panels. 
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Figure 5. BRD4 enhancer occupancy and regulation of select eRNAs and genes is modulated by BRD4 interactions 
with eRNAs. 
a, qRT-PCR analysis of MMP9 and CCL2 eRNAs and mRNAs and b, immunoblot analysis of SW480 cells stably 
expressing control (Ctrl) or MMP9 and CCL2 eRNA shRNAs and treated with TNF-α for 0 or 16 hr. c, IgG, BRD4, and 
RNAPII ChIP-qPCR analyses at the enhancers (A) and nonspecific (B) regions of MMP9 and CCL2 gene loci in SW480 
cells described in (a) and treated with TNF-α for 16 hr. The average of at least two independent ChIP experiments that are 
representative of three is shown with error bars denoting the standard error. d, qRT-PCR and immunoblot analysis of 
BRD4 mRNA and protein levels in SW480 cells that expressed control or BRD4 shRNAs together with empty vector 
control or shRNA-resistant plasmids expressing BRD4 FL or BRD4 𝛥BD1/2 and treated with TNF-α for 16 hr. e, qRT-
PCR analysis of MMP9 and CCL2 eRNA and mRNA expression levels in single BRD4 or double BRD4 and MMP9 or 
CCL2 eRNA knockdown SW480 cells that were transiently transfected with shRNA-resistant constructs expressing BRD4 
FL or BRD4 ΔBD1/2 and treated with TNF-α for 16 hr. For all eRNA and mRNA expression analyses in (a), (d), and (e), 
the expression levels following TNF-α treatment are relative to the levels before TNF-α and bar graphs represent the 
average of three independent experiments with the error bars denoting the standard error. Statistical significance was 
determined by two-tailed Student’s t-test. * indicates p-value <0.05. ns: no significance. 
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Figure 6. Proposed model for eRNA-mediated BRD4 tethering to acetylated histones at active enhancers. 
Upon chronic TNF-α signaling, NFκB recruits mutp53 to a subset of enhancers as we have previously described48. In our 
current study, we show that BRD4 is also recruited to these mutp53-activated enhancers following chronic immune 
signaling. Subsequently, eRNAs synthesized from the activated enhancers bind to the bromodomains of BRD4 to enhance 
its binding to acetylated chromatin. This stabilization of BRD4 at active enhancers contributes to TNF-α-induced 
production of eRNAs and potent expression of the nearby tumor promoting genes.  
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Supplementary Figure 1. BRD4 cooperates with mutp53 at active enhancers to regulate enhancer and gene 
activation upon chronic immune signaling. 
a, Venn diagram depicting the overlap between p53 R273H and BRD4 binding sites at H3K27ac and H3K4me1 enriched, 
intergenic regions in SW480 cells after 16 hr TNF-α treatment. b, De novo motif analyses of the BRD4 and p53 R273H 
co-bound ChIP-seq peaks at active enhancer regions. c, (Top) schematics of ChIP-qPCR amplicons and (bottom) ChIP-
qPCR analysis of sequential ChIP with p53 antibody followed by BRD4 and control IgG antibody in SW480 treated with 
TNF-α for 16 hr at the enhancer (A) and nonspecific (B) regions of MMP9 and CCL2 gene loci. d, Immunoblot analysis of 
BRD4 Co-IP performed with lysates from SW480 cells treated with TNF-α for 0, 16 hr with indicated antibodies. e, (Top) 
immunoblot analysis of direct interaction assay between BRD4 and p53 (wild-type and R273H) using (bottom) 
recombinant proteins analyzed by SDS-PAGE and coomassie staining. Co-IP and binding assays were performed three 
independent times with representative images for each assay shown in the corresponding panels. f, Immunoblot analysis of 
SW480 cells stably expressing LacZ (Ctrl) or p53 shRNA and treated with TNF-α for 0 or 16 hr with the indicated 
antibodies. g, qRT-PCR analysis of MMP9 and CCL2 eRNAs and mRNAs in SW480 cells stably expressing control (Ctrl) 
or a second BRD4 shRNA oligo (BRD4-2) and treated with TNF-α for 0 or 16 hr. h, ChIP-qPCR analysis of IgG and p53 
R273H enrichment at the enhancer (A) and nonspecific (B) regions of MMP9 and CCL2 gene loci in SW480 cells stably 
expressing control or BRD4 shRNA and treated with TNF-α for 0 or 16 hr. i, Immunoblot (top) and qRT-PCR analysis 
(bottom) of SW480 cells treated with vehicle (DMSO) or JQ1 and TNF-α for 0 or 16 hr. In (g) and (i) the expression levels 
following TNF-α treatment are relative to the levels before TNF-α exposure and bar graphs represent the average of three 
independent experiments with the error bars denoting the standard error. In (c) and (h) the average of at least two 
independent ChIP experiments that are representative of three is shown with error bars denoting the standard error. 
Statistical significance was determined by two-tailed Student’s t-test. * indicates p-value <0.05. 
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Supplementary Figure 2. BRD4 directly interacts with RNAs. 
a, qRT-PCR and immunoblot analyses of SW480 cells treated with TNF-α for 0 or 16 hr. b, UV-RIP qPCR analysis of the 
CSF2 and TNFAIP3 eRNAs following IgG or BRD4 IP in SW480 cells treated with TNF-α for 0 or 16 hr. Enrichment 
levels for each TNF-α treated IP is relative to the levels before TNF-α treatment. The bar graphs represent the average of 
three independent UV-RIP experiments with the error bars denoting the standard error. Statistical significance was 
determined by two-tailed Student’s t-test. * indicates p-value <0.05. c, UCSC genome browser images of GRO-seq and 
BRD4 ChIP-seq signals in SW480 cells treated as described in (a) at active enhancer regions of CSF2 and TNFAIP3. d, 
SYBR Gold staining of in vitro binding assay between BRD4 FL and various in vitro transcribed RNA molecules. Three 
independent in vitro binding assays were performed. e, Quantification of RNA EMSAs to determine the fraction of RNA 
bound to BRD4 FL as shown in Fig. 3a and BRD4 ΔBD1/2 as shown in Fig. 3e. 
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Supplementary Figure 3. eRNAs enhance BRD4 binding to acetylated histone peptides and octamers in vitro. 
a, Immobilized peptide pulldown assay using biotinylated H4 peptides (unmodified or K16acetylated-modified) with either 
recombinant BRD4 FL or BRD4 𝛥BD1/2 in the absence or presence of refolded CCL2 eRNA as indicated. Recombinant 
BRD4 FL and BRD4 𝛥BD1/2 were detected by immunoblotting with an antibody specific to BRD4. b, Immunoblot 
analysis of in vitro binding assays with unacetylated or acetylated histone octamers, recombinant BRD4 FL or 𝛥BD1/2, 
and refolded CCL2 eRNA as indicated. c, In vitro histone octamer binding assay as described in (b) with recombinant 
BRD4 FL and increasing doses of refolded MMP9 eRNA (0.06, 0.1, 0.2, 1, and 2 nM). In (b) and (c), immunoblot analysis 
with H3K27ac and H3K9ac antibodies confirmed the p300- and acetyl-CoA-mediated acetylation of the histone octamers. 
Lower panels in (a), (b), and (c) represent the loading of the indicated proteins by coomassie staining. All in vitro binding 
assays were performed three independent times. 
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Supplementary Figure 4. eRNA depletion reduces the expression of corresponding mRNAs and impacts BRD4 
binding. 
a, qRT-PCR analysis of MMP9 and CCL2 eRNAs and mRNAs in SW480 cells expressing control or a second shRNA 
oligo against MMP9 and CCL2 eRNAs and treated with TNF-α for 0 or 16 hr. b, qRT-PCR analysis of CPA4 and 
CYP24A1 eRNA and mRNAs in SW480 cells treated as described in Fig. 5a. c, Immunoblot and d, qRT-PCR analysis of 
SW480 cells treated with TNF-α for 0 or 16 hr and treated with Actinomycin D for 2 hr. In (a), (b), and (c), the expression 
levels following TNF-α treatment are relative to the levels before TNF-α exposure. The bar graphs represent the average of 
three independent experiments. e, ChIP-qPCR analyses of IgG and BRD4 enrichment in SW480 cells treated as described 
in (c), at the enhancer (A) and nonspecific (B) regions of MMP9 and CCL2 gene loci. An average of two independent ChIP 
experiments that are representative of three is shown with error bars denoting the standard error. 
